Page last updated: 2024-12-06

hexadecanamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Hexadecanamide, also known as palmitamide, is a long-chain fatty acid amide naturally occurring in mammals. It is synthesized from palmitic acid, a saturated fatty acid, and is involved in various physiological processes. Research suggests that hexadecanamide plays a role in regulating appetite, sleep, and inflammation. It has also been found to exhibit anti-inflammatory and analgesic properties. Studies on hexadecanamide focus on understanding its role in biological systems, its potential therapeutic applications, and its interactions with other molecules. Its importance lies in its potential to be developed as a drug for treating conditions such as obesity, insomnia, and chronic pain.'

hexadecanamide : A fatty amide that is the carboxamide derived from palmitic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69421
CHEMBL ID32605
CHEBI ID74475
SCHEMBL ID43384
SCHEMBL ID23571900
MeSH IDM0062252

Synonyms (39)

Synonym
AKOS015839800
cetyl amide
amide hpl
palmitic acid amide
palmitamide
nsc3327
palmitic amide
629-54-9
n-hexadecanamide
palmityl amide
nsc-3327
amide 16
hexadecanamide
NCGC00161182-02
chebi:74475 ,
CHEMBL32605
hexadecanoic acid amide
H0067
LMFA08010009
nsc 3327
unii-qx1mq82m73
einecs 211-095-5
qx1mq82m73 ,
FT-0626967
palmitamide [inci]
palmitamide (palmitic acid amide)
SCHEMBL43384
HSEMFIZWXHQJAE-UHFFFAOYSA-N
DTXSID8044707
c16h33no
mfcd00025534
palmitamide (acd/name 4.0)
Q18651888
2,6-dichloro-4-nitropyridine?
AS-56522
bdbm50463964
SCHEMBL23571900
CS-0081845
SY038954
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
primary fatty amideA primary carboxamide RC(=O)NH2 resultng from the formal condensation of the carboxy group of a fatty acid with ammonia.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.07950.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 2Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.03701.93458.6000AID1400243; AID1400244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID49296Percent inhibition of specific binding of [3H]CP-55940 towards human cannabinoid receptor 1 from Chinese hamster ovary cell membranes at the concentration of 10 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
AID195691Inhibition of [3H]- AEA metabolism (N-arachidonoylethanolamine) in rat brain homogenates using [3H]anandamide as the labeled substrate.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
AID49691Percent inhibition of specific binding of [3H]WIN-55212-2 towards human cannabinoid receptor 2 from Chinese hamster ovary cell membranes at the concentration of 10 uM2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
AID387967Antiproliferative activity against human WI38 cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID387968Antiproliferative activity against mouse RAW264.7 cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID195561Percent inhibition of AEA (N-arachidonoylethanolamine) metabolism in rat brain homogenates using [3H]anandamide as the labeled substrate.2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide.
AID71618Relative rate of fatty acid amide hydrolase hydrolysis of compound compared to that of oleamide.2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Fatty acid amide hydrolase substrate specificity.
AID1400244Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of CBD-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID1400243Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of LPC-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's4 (33.33)24.3611
2020's4 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.20 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index40.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]